Stocklytics Platform
Asset logo for symbol PLRX
Pliant Therapeutics
PLRX53
$10.62arrow_drop_down11.21%-$1.33
Asset logo for symbol PLRX
PLRX53

$10.62

arrow_drop_down11.21%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Pliant Therapeutics (PLRX) Stocklytics Forecast

Pliant Therapeutics Inc (PLRX) is a biopharmaceutical company that focuses on the development of novel therapies for fibrotic diseases. The company's primary objective is to address the unmet medical needs of patients suffering from these debilitating conditions. With its innovative approach and cutting-edge research, PLRX has garnered significant attention in the healthcare industry.
As for the stock price prediction of PLRX, it is important to note that predicting stock prices with complete accuracy is a challenging task. However, analysts and market experts have provided their forecasts and assessments based on various factors. These predictions can be useful for investors to make informed decisions.
add Pliant Therapeutics  to watchlist

Keep an eye on Pliant Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Pliant Therapeutics (PLRX) stock?

Analysts have set a target price of $45.25 for Pliant Therapeutics (PLRX), based on forecasts from 24 analysts. The predicted price range extends from a high of $63 to a low of $36. This represents a potential increase of up to 492.94% and a decrease of 238.82% from the current price of $10.62. These forecasts are as of 2023 May 18.
help

What are the analyst ratings for Pliant Therapeutics (PLRX) stock?

Currently, there are no analyst ratings available for Pliant Therapeutics (PLRX), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Pliant Therapeutics (PLRX) stock?

At present, there is no AI or machine-learning-based price prediction available for Pliant Therapeutics (PLRX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level